Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Intellia Therapeutics

Intellia Therapeutics (NASDAQ: NTLA) insider transactions

In the twelve months to 10 November 2026, executives and directors of Intellia Therapeutics reported 19 open-market sales of 222,769 shares ($2.3m) and 1 open-market purchase of 150,000 shares ($1.4m), by 8 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Intellia Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
2 November 2026Leonard John MPresident and CEOOpen-market sale, 10b5-1 plan−9,000$11.991,138,064Form 4
26 October 2026Marantz Jing L.EVP, Chief Medical OfficerGrant or award+199,822—199,822Form 4
2 October 2026Dube Michael PVP, Chief Accounting OfficerOpen-market sale−1,864$12.4365,022Form 4
21 August 2026Leonard John MPresident and CEOOpen-market sale−2,785$13.001,147,064Form 4
20 August 2026Leonard John MPresident and CEOOpen-market sale−19,890$12.601,149,849Form 4
22 July 2026Dulac Edward J IIIEVP, Chief Financial OfficerOpen-market sale−8,111$11.25148,175Form 4
2 July 2026Dulac Edward J IIIEVP, Chief Financial OfficerOpen-market sale−4,677$18.00156,286Form 4
1 July 2026Dube Michael PVP, Chief Accounting OfficerOpen-market sale−2,641$16.7866,886Form 4
9 June 2026Bhanji MunaDirectorGrant or award+9,200—36,403Form 4
9 June 2026Cohen Fred EDirectorGrant or award+9,200—216,653Form 4
9 June 2026Goff BrianDirectorGrant or award+9,200—32,609Form 4
9 June 2026Keresty GeorgiaDirectorGrant or award+9,200—41,083Form 4
9 June 2026Verwiel FrankDirectorGrant or award+9,200—35,148Form 4
9 June 2026Chase William JDirectorGrant or award+9,200—143,893Form 4
9 June 2026Goodman JesseDirectorGrant or award+9,200—33,559Form 4
2 March 2026Clark ElianaEVP, Chief Technical OfficerOpen-market sale−607$13.7893,864Form 4
2 March 2026Basta JamesEVP, General CounselOpen-market sale−1,211$13.78156,794Form 4
1 March 2026Dube Michael PVP, Chief Accounting OfficerGrant or award+17,250—69,527Form 4
1 March 2026Clark ElianaEVP, Chief Technical OfficerGrant or award+7,353—94,471Form 4
1 March 2026Schultes Birgit CEVP, Chief Scientific OfficerGrant or award+39,200—137,733Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Intellia Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.